Fibrotic extracellular matrix activates a profibrotic positive feedback loop

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1622-1635

  Parker, Matthew W ^a,b   Rossi, Daniel ^a   Peterson, Mark ^a   Smith, Karen ^a   Sikstrom̈, Kristina ^b   White, Eric S ^c   Connett, John E ^d   Henke, Craig A ^a   Larsson, Ola ^b   Bitterman, Peter B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 29; SCLEROPROTEIN; TRANSCRIPTOME;

ADULT; ARTICLE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; GENE CONTROL; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG PARENCHYMA; OVERLAPPING GENE; POLYSOME; POSITIVE FEEDBACK; PRIORITY JOURNAL; RNA STABILITY; STEADY STATE; UPREGULATION;

AGED; CASE-CONTROL STUDIES; CELL LINE; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FEEDBACK, PHYSIOLOGICAL; FIBROBLASTS; GENE EXPRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MICRORNAS; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN BIOSYNTHESIS;

EID: 84897507640     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71386     Document Type: Article

References (62)

1. Halliday NL, Tomasek JJ. Mechanical properties of the extracellular matrix influence fibronectin fibril assembly in vitro. Exp Cell Res. 1995;217(1):109-117.
2. Pelham RJ Jr, Wang Y. Cell locomotion and focal adhesions are regulated by the mechanical properties of the substrate. Biol Bull. 1998;194(3):348-350. (Pubitemid 28338467)
3. Rhudy RW, McPherson JM. Influence of the extracellular matrix on the proliferative response of human skin fibroblasts to serum and purified platelet-derived growth factor. J Cell Physiol. 1988;137(1):185-191.
4. Schor SL. Cell proliferation and migration on collagen substrata in vitro. J Cell Sci. 1980;41(1):159-175. (Pubitemid 10054369)
5. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432(7015):332-337. (Pubitemid 39551661)
6. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev. 2006;6(5):392-401.
7. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002;296(5570):1046-1049. (Pubitemid 34517108)
8. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040.
9. Hinz B, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-1355.
10. Selman M, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136-151. (Pubitemid 32096342)
11. Noble PW, et al. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin Chest Med. 2004;25(4):749-758. (Pubitemid 39556507)
12. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-1961.
13. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair the fibroblast reticulum. Am J Respir Crit Care Med. 2006;174(6):654-658. (Pubitemid 44395332)
14. Agustí AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1991;143(2):219-225.
15. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med. 2006;27(1):S11-S16.
16. Frankel SK, et al. Tnf- ± sensitizes normal and fibrotic human lung fibroblasts to fas-induced apoptosis. Am J Respir Cell Mol Biol. 2006; 34(3):293-304. (Pubitemid 43320710)
17. Moodley YP, et al. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol. 2003;163(1):345-354. (Pubitemid 36759619)
18. Ramos C, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24(5):591-598. (Pubitemid 32442767)
19. Xia H, et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med. 2008;205(7):1659-1672. (Pubitemid 351962029)
20. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res. 2001;3:13.
21. McKeown S, Richter AG, O'Kane C, McAuley DF, Thickett D. Mmp expression and abnormal lung permeability are important determinants of outcome in ipf. Eur Respir J. 2009;33(1):77-84.
22. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali- Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005;166(2):399-407. (Pubitemid 40189037)
23. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3(4):350-356. (Pubitemid 43845412)
24. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24):4195-4200.
25. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 2000;46(2):257-263. (Pubitemid 30204597)
26. Zhou Y, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096-1108.
27. Larsson O, Tian B, Sonenberg N. Toward a genome-wide landscape of translational control. Cold Spring Harb Perspect Biol. 2013;5(1):a012302.
28. Larsson O, et al. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 2008;3(9): e3220.
29. Emblom-Callahan M, et al. Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 2010;96(3):134-145.
30. Konishi K, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180(2):167-175.
31. Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 2009;324(5924):218-223.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289-300.
33. Vuga L, et al. Wnt5a is a regulator of fibroblast proliferation and resistance to apoptosis. Am J Respir Cell Mol Biol. 2009;41(5):583-589.
34. Larsson O, Sonenberg N, Nadon R. Identification of differential translation in genome wide studies. Proc Natl Acad Sci U S A. 2010;107(50):21487-21492.
35. Larsson O, Sonenberg N, Nadon R. anota: analysis of differential translation in genome-wide studies. Bioinformatics 2011;27(10):1440-1441.
36. Colman H, et al. Genome-wide analysis of host mrna translation during hepatitis c virus infection. J Virol. 2013;87(12):6668-6677.
37. Luo W, Friedman M, Shedden K, Hankenson K, Woolf P. Gage: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics. 2009;10:161.
38. Booth A, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med. 2012;186(9):866-876.
39. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731-745.
40. Cushing L, et al. mir-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(2):287-294.
41. Pandit K, Milosevic J, Kaminski N. Micrornas in idiopathic pulmonary fibrosis. Transl Res. 2011;157(4):191-199.
42. Schwanhäusser B, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337-342.
43. Oak SR, et al. A micro rna processing defect in rapidly progressing idiopathic pulmonary fibrosis. PloS One. 2011;6(6):e21253.
44. Maurer B, et al. Microrna-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62(6):1733-1743.
45. Qin W, et al. Tgf-β/smad3 signaling promotes renal fibrosis by inhibiting mir-29. J Am Soc Nephrol. 2011;22(8):1462-1474.
46. Van Rooij E, et al. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027-13032.
47. Xiao J, et al. mir-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther. 2012;20(6):1251-1260.
48. Yang T, et al. Mir-29 mediates tgf ? 1- induced extracellular matrix synthesis through activation of pi3k-akt pathway in human lung fibroblasts. J Cell Biochem. 2013;114(6):1336-1342.
49. Matthews L, et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009;37(suppl 1):D619-D622.
50. Lwebuga-Mukasa JS, Ingbar DH, Madri JA. Repopulation of a human alveolar matrix by adult rat type ii pneumocytes in vitro: a novel system for type ii pneumocyte culture. Exp Cell Res. 1986;162(2):423-435. (Pubitemid 16131242)
51. Li S, et al. Translation factor eif4e rescues cells from myc-dependent apoptosis by inhibiting cytochromec release. J Biol Chem. 2003;278(5):3015-3022. (Pubitemid 36801209)
52. Weisberg HS, Fox J. An R Companion To Applied Regression. 2nd ed. Thousand Oaks, California, USA: Sage Publications, Inc.; 2010.
53. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003;19(18):2448-2455. (Pubitemid 38016644)
54. Ashburner M, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25-29. (Pubitemid 30257031)
55. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell. 2005;120(1):15-20. (Pubitemid 40094598)
56. Chen C, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid dna. Biotechniques. 1987;6(7):632-638.
57. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998;72(10):8150-8157.
58. Mochizuki H, Schwartz JP, Tanaka K, Brady RO, Reiser J. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol. 1998;72(11):8873-8883. (Pubitemid 28471831)
59. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus g glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 1993;90(17):8033-8037. (Pubitemid 23260849)
60. Zufferey R, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873-9880. (Pubitemid 28520853)
61. Dull T, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. (Pubitemid 28471781)
62. Ellis BL, Potts PR, Porteus MH. Creating higher titer lentivirus with caffeine. Hum Gene Ther. 2010;22(1):93-100.